Download PDF
Horm Metab Res 2020; 52(07): 485-491
DOI: 10.1055/a-1160-9902
Review

The Effects of Vitamin D on Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Systematic Review

Ashley Williams
1   Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, AL, USA
,
Jeganathan Ramesh Babu
1   Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, AL, USA
2   Boshell Metabolic Diseases and Diabetes Program, Auburn University, Auburn, AL, USA
,
Danielle D. Wadsworth
3   School of Kinesiology, Auburn University, Auburn, AL, USA
,
Donna Burnett
1   Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, AL, USA
,
Thangiah Geetha
1   Department of Nutrition, Dietetics, and Hospitality Management, Auburn University, AL, USA
2   Boshell Metabolic Diseases and Diabetes Program, Auburn University, Auburn, AL, USA
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

This systematic review aims to evaluate all epidemiological evidence in the literature linking the effect of vitamin D supplementation to metabolic and hormonal functions in women with polycystic ovary syndrome. The literature search was performed with two databases, namely Medline/PubMed and Web of Science, until 20 May 2019 for both observational and experimental studies concerning relationships between vitamin D and polycystic ovary syndrome. A total of ten studies with randomized, double-blinded, and placebo-controlled trial design from 2008 to 2019 were selected for this review. The inclusion criteria were women 18–45 years of age with polycystic ovary syndrome and comparing the metabolic or endocrine parameters between placebo and vitamin D supplementation groups. A total of ten studies were selected for this review. We found that vitamin D supplementation had a significant effect on insulin metabolism, total serum testosterone, hirsutism, C-reactive protein, and total antioxidant capacity in women with polycystic ovary syndrome. Evidence from available randomized controlled trials suggests that patients with polycystic ovary syndrome should take vitamin D supplementation for the beneficial effect of metabolic profiles. However, future research is needed regarding the beneficial effects in women who are non-obese with polycystic ovary syndrome, as well as more studies with larger sample sizes.

Key words

polycystic ovary syndrome - vitamin D - systematic review - randomized controlled trials


Publication History

Received: 25 March 2020

Accepted: 09 April 2020

Article published online:
18 May 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Fica S, Albu A, Constantin M. et al. Insulin resistance and fertility in polycystic ovary syndrome. J Med Life 2008; 1: 415-422
    PubMedGoogle Scholar
  • 2 Rashidi H, Toolabi M, Najafian M. et al. The relationship of serum 25-dihydroxy vitamin D3 concentrations with metabolic parameters in non-obese women with polycystic ovarian syndrome. Middle East Fertil Soc J 2016; 21: 264-268
    CrossrefPubMedGoogle Scholar
  • 3 Patra SK, Nasrat H, Goswami B. et al. Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome. Diabetes Metab Syndr 2012; 6: 146-149
    CrossrefPubMedGoogle Scholar
  • 4 He C, Lin Z, Robb SW. et al. Serum vitamin D levels and polycystic ovary syndrome: A systematic review and meta-analysis. Nutrients 2015; 7: 4555-4577
    CrossrefPubMedGoogle Scholar
  • 5 Javed Z, Papageorgiou M, Deshmukh H. et al. A Randomized, controlled trial of vitamin D supplementation on cardiovascular risk factors, hormones, and liver markers in women with polycystic ovary syndrome. Nutrients 2019; 11: 188
    CrossrefPubMedGoogle Scholar
  • 6 Fang F, Ni K, Cai Y. et al. Effect of vitamin D supplementation on polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Clin Pract 2017; 26: 53-60
    CrossrefPubMedGoogle Scholar
  • 7 Ostadmohammadi V, Jamilian M, Bahmani F. et al. Vitamin D and probiotic co-supplementation affects mental health, hormonal, inflammatory and oxidative stress parameters in women with polycystic ovary syndrome. J Ovarian Res 2019; 12: 5
    CrossrefPubMedGoogle Scholar
  • 8 Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 77: 343-350
    CrossrefPubMedGoogle Scholar
  • 9 Demer LL, Hsu JJ, Tintut Y. Steroid Hormone Vitamin D: Implications for cardiovascular disease. Circ Res 2018; 122: 1576-1585
    CrossrefPubMedGoogle Scholar
  • 10 Hilger J, Friedel A, Herr R. et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr 2014; 111: 23-45
    CrossrefPubMedGoogle Scholar
  • 11 Rashidi H, Ghaderian SB, Moradi L. The effect of vitamin D3 on improving lipid profile, fasting glucose and insulin resistance in polycystic ovary syndrome women with vitamin D deficiency. Middle East Fertil Soc J 2018; 23: 178-183
    CrossrefPubMedGoogle Scholar
  • 12 Lagunova Z, Porojnicu AC, Lindberg F. et al. The dependency of vitamin D status on body mass index, gender, age and season. Anticancer Res 2009; 29: 3713-3720
    PubMedGoogle Scholar
  • 13 Parikh SJ, Edelman M, Uwaifo GI. et al. The relationship between obesity and serum 1,25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004; 89: 1196-1199
    CrossrefPubMedGoogle Scholar
  • 14 Xue Y, Xu P, Xue K. et al. Effect of vitamin D on biochemical parameters in polycystic ovary syndrome women: A meta-analysis. Arch Gynecol Obstet 2017; 295: 487-496
    CrossrefPubMedGoogle Scholar
  • 15 Jamilian M, Foroozanfard F, Rahmani E. et al. Effect of two different doses of vitamin D supplementation on metabolic profiles of insulin-resistant patients with polycystic ovary syndrome. Nutrients 2017; 9: 1280
    CrossrefPubMedGoogle Scholar
  • 16 Pal L, Berry A, Coraluzzi L. et al. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 965-968
    CrossrefPubMedGoogle Scholar
  • 17 Tehrani HG, Mostajeran F, Shahsavari S. The effect of calcium and vitamin D supplementation on menstrual cycle, body mass index and hyperandrogenism state of women with poly cystic ovarian syndrome. J Res Med Sci 2014; 19: 875-880
    PubMedGoogle Scholar
  • 18 Dastorani M, Aghadavod E, Mirhosseini N. et al. The effects of vitamin D supplementation on metabolic profiles and gene expression of insulin and lipid metabolism in infertile polycystic ovary syndrome candidates for in vitro fertilization. Reprod Biol Endocrinol 2018; 16: 94
    CrossrefPubMedGoogle Scholar
  • 19 Maktabi M, Chamani M, Asemi Z. The effects of vitamin D supplementation on metabolic status of patients with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Horm Metab Res 2017; 49: 493-498
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Raja-Khan N, Shah J, Stetter CM. et al. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: A randomized, controlled pilot trial. Fertil Steril 2014; 101: 1740-1746
    CrossrefPubMedGoogle Scholar
  • 21 Trummer C, Schwetz V, Kollmann M. et al. Effects of vitamin D supplementation on metabolic and endocrine parameters in PCOS: A randomized controlled trial. Eur J Nutr 2019; 58: 2019-2028
    CrossrefPubMedGoogle Scholar
  • 22 Foroozanfard F, Jamilian M, Bahmani F. et al. Calcium plus vitamin D supplementation influences biomarkers of inflammation and oxidative stress in overweight and vitamin D-deficient women with polycystic ovary syndrome: A randomized double-blind placebo-controlled clinical trial. Clin Endocrinol (Oxf) 2015; 83: 888-894
    CrossrefPubMedGoogle Scholar
  • 23 Wehr E, Pieber TR, Obermayer-Pietsch B. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: a pilot study. J Endocrinol Invest 2011; 34: 757-763
    PubMedGoogle Scholar
  • 24 Kern PA, Ranganathan S, Li C. et al. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751
    CrossrefPubMedGoogle Scholar
  • 25 Federici M, Hribal ML, Menghini R. et al. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 2005; 115: 3494-3505
    CrossrefPubMedGoogle Scholar
  • 26 Monroy A, Kamath S, Chavez AO. et al. Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: A new mechanism of insulin resistance in humans. Diabetologia 2009; 52: 2169-2181
    CrossrefPubMedGoogle Scholar
  • 27 Tripathy D, Daniele G, Fiorentino TV. et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 2013; 56: 2153-2163
    CrossrefPubMedGoogle Scholar